Influenza Vaccines for the World

19-21 April 2017, CHUVUniversity of Lausanne, Lausanne, Switzerland

  • Increase font size
  • Default font size
  • Decrease font size

Day Three

Final Conference Programme | Friday 21st April 2017

SESSION 9:
UNIVERSAL INFLUENZA VACCINES – II

Moderator: Sarah Gilbert (University of Oxford, Oxford, UK)

09.00-09.30
‘What is needed for the ultimate influenza vaccine?’
Rob Lambkin-Williams (hVIVO Ltd, London, UK)

09.30-09.50
‘Recombinant adenovirus expressing influenza HA can effectively prime for heterologous neutralizing antibody responses’
Sean Tucker (VAXART Inc., South San Francisco, California, USA)

09.50-10.10
‘Results of a Phase 1a study of M2SR influenza vaccine in healthy adults’
Pamuk Bilsel (FluGen Inc., Madison, Wisconsin, USA)

10.10-10.30
‘Novel MVA-based vaccines expressing conserved influenza antigens activate cross-reactive T and B cell responses in human NALT against influenza virus’
Qibo Zhang1, Suttida Puksuriwong1, Muhammad S. Ahmed1, Ravi Sharma2, Madhan Krishnan2, Anna Markey2, Max McCormick3, Teresa Lambe5, Paul McNamara4 and Sarah C. Gilbert5 (1 Institute of Infection and Global Health, University of Liverpool, Liverpool, UK; 2 ENT Department, Alder Hey Children’s Hospital, Liverpool, UK; 3 ENT Department, Royal Liverpool and Broadgreen University Hospitals, Liverpool, UK; 4 Institute of Child Health, Alder Hey Children’s Hospital, Liverpool, UK; 5 The Jenner Institute, University of Oxford, Oxford, UK)

10.30-10.50
‘Large variation in effects of influenza vaccines pre- and post-2009 influenza H1N1 pandemic among community-dwelling older persons’
E. Hak (University Groningen, Groningen, The Netherlands)

10.50-11.10
Coffee Break & Posters

SESSION 10:
FORMULATION, VACCINATION & REACTOGENICITY

Moderator: Rob Lambkin-Williams (hVIVO Ltd, London, UK)

11.10-11.30
‘Rational vaccine formulation development using QbD Principles’
Manmohan Singh (Takeda Vaccines, Inc., Cambridge, Massachusetts, USA)

11.30-11.50
‘Vaccinating in the presence of pre-existing immune responses’
Donald M. Carter1, Christopher A. Darby1, Timothy Alefantis2, Joshua DiNapoli2, Harold Kleanthous2 and Ted M. Ross1 (1 University of Georgia, Athens, Georgia, USA; 2 Sanofi-Pasteur, Inc., Discovery Research, Cambridge, Massachusetts, USA)

11.50-12.10
‘Vaccination with self-adjuvanted protein nanoparticles provides protection against lethal influenza challenge’
Christopher Karch1, Jianping Li2, Caroline Kulangara3, Sara M. Paulillo3, Senthil K. Raman3, Sharareh Emadi4, Anmin Tan4, Zeinab H. Helal2,5, Qing Fan2,6, Mazhar I. Khan2 and Peter Burkhard3 (1 University of Connecticut, Storrs, Connecticut, USA; 2 Department of Pathobiology and Veterinary Science, University of Connecticut, Storrs, Connecticut, USA; 3 Alpha-O Peptides AG, Riehen, Switzerland; 4 Institute of Materials Science, University of Connecticut, Storrs, Connecticut, USA; 5 Department of Microbiology and Immunology, Faculty of Pharmacy, Alazhar-University, Cairo, Egypt; 6 Department of Biotechnology, Guangxi Veterinary Research Institute, Nanning, Guangxi, China)

12.10-12.30
‘Rapid assessment of the reactogenicity of a 2016-2017 seasonal influenza vaccine: Results from a feasibility study’
Anke L. Stuurman1, Thomas Verstraeten1 and Antoon De Schryver2 (1 P95 Epidemiology and Pharmacovigilance Consulting and Services, Leuven, Belgium; 2 IDEWE, Leuven,

12.30-12.50
‘Infection-permissive immunity against influenza virus provided by vaccination prevents loss of alveolar macrophages and modulates virus-induced cross-reactive cellular immune responses during subsequent influenza infections’
Angela Choi1, Joselin Andrea Morales Mina1, Jan Spitaels2,3, Adolfo García-Sastre1,3 and Michael Schotsaert1 (1 Icahn School of Medicine at Mount Sinai, New York, New York, USA; 2 Ghent University Department of Biomedical Molecular Biology, Ghent, Belgium; 3 Global Health and Emerging Pathogens Institute, Department of Medicine, Icahn School of Medicine at Mount Sinai New York, New York, USA)

12.50-13.10
‘Impact of prior influenza exposures on H3N2 cross-reactivity of human post-vaccination sera’
Hang Xie1, Lei Li2, Zhiping Ye1, Xing Li1, Ewan P. Plant1, Olga Zoueva1, Yangqing Zhao1, Xianghong Jing1, Zhengshi Lin1, Toshiaki Kawano1, Meng-Jung Chiang1, Courtney Finch1, Martina Kosikova1, Anding Zhang1, Yanhong Zhu1 and Xiu-Feng Wan2 (1 Center for Biologics Evaluation and Research, United States Food and Drug Administration (CBER/FDA), Silver Spring, Maryland, USA; 2 Mississippi State University, Mississippi, USA)

13.10-14.00
Lunch Break & Posters

SESSION 11:
EVALUATION, EFFICACY & SAFETY

Moderator: Dirk Poelert (GlaxoSmithKline, Wavre, Belgium)

14.00-14.20
‘Non-clinical investigations into the reduced effectiveness of the H1N1pdm09 component of the live attenuated influenza vaccine’
Helen Bright (MedImmune Ltd, Liverpool, Merseyside, UK)

14.20-14.40
‘Observational study comparing safety of Flublok with a traditional egg-derived inactivated influenza vaccine’
Manon Cox (Protein Sciences Corporation, Meriden, Connecticut, USA)

14.40-14.55
‘Improving the safety of a whole influenza virus vaccine through delipidation’
Motuharu Abe, Kazuyuki Ikeda, Ryo Yamaue, Issei Asano, Hiroto Onuma, Yusuke Ohyama, Kenta Matsuura, Hiroaki Mori, Kazuhiko Kimachi and Yoichiro Kino (Kaketsuken, Kumamoto, Japan)

14.55-15.10
‘Influenza vaccine effectiveness and safety in Italy season 2015/16’
Valeria Alfonsi1, Antonino Bella1, Patrizia Felicetti2, Stefania Spila Alegiani1 and Caterina Rizzo1 (1 Istituto Superiore di Sanità, Rome, Italy; 2 Italia Medicines Agency AIFA, Rome, Italy)

15.10-15.25
Tea Break & Poster Breakdown

SESSION 12:
CLOSING PLENARY

Moderator: John Oxford (Queen Mary College, University of London, London, UK)

CLOSING PLENARY PRESENTATIONS

15.25-16.05
‘Influenza prevention: Vaccination uptake stagnation – a global public health failure?’
Bram Palache (Independent Consultant, IFPMA, International Federation of Pharmaceutical Manufacturers & Associations, Geneva, Switzerland)

16.05-16.25
‘Statins, influenza vaccination and influenza‘
David Fedson (Independent Consultant, Sergy Haut, France)

16.25-16.45
‘Influenza Vaccines – The Continuing Challenge’
Ab Osterhaus (University of Veterinary Medicine Hannover, Hannover, Germany)

16.45
Conference Close & Departure

* This final programme is correct at the time of publication. However the organizers reserve the right to make any alterations that may be required in the interests and integrity of the conference programme.

 

IVW 2017 Delegates

Login details will be supplied after you have registered for the event.


IVW 2017 Sponsors

  • MedicaGo
  • APACI
  • ISIRV
  • Fraunhofer
  • Biondvax
  • MedImmune
  • Janssen
  • InDevR
  • VisMederi
  • Sanofi Pasteur
  • Vaxart
  • Nanopass
  • Eurocine Vaccines
  • hVIVO
  • Inovio
  • FluConsult
  • Protein Sciences

IVW 2017 Downloads

IVW 2017 Leaflet

IVW 2017 Mailing List

Name
E-mail Address
What is 3+2-1?